Inbiomotion

Inbiomotion SL, a spin-off from the Institució Catalana de Recerca i Estudis Avançats (ICREA) and the Institut d'Investigació Biomèdica (IRB Barcelona), was established in Barcelona, Spain in 2011. The company operates in the biotechnology sector, focusing on the development of a diagnostic test to guide treatment for breast cancer patients. Its foundation is built upon the research of its founder, Dr. Roger Gomis. His work at the IRB Barcelona centered on understanding the mechanisms of cancer metastasis, specifically identifying the MAF (mesenchymal-epithelial transition activating factor) gene's role in predicting which early-stage breast cancer patients are at a higher risk of relapse and bone metastasis.

The core of Inbiomotion's business is its proprietary in-vitro diagnostic test, MAF Test®, designed to stratify patients based on the expression of the MAF gene. This test analyzes tumor samples to determine if the gene is functioning abnormally, which indicates a higher likelihood of the cancer spreading. For patients identified with this specific gene signature, the test provides crucial information for oncologists to personalize treatment. Specifically, it can predict a patient's response to bisphosphonates, a class of drugs commonly used to treat osteoporosis, which have shown efficacy in preventing bone metastasis in this patient subgroup.

The company's business model revolves around the commercialization of this diagnostic tool, targeting pathology labs and oncologists within hospitals and cancer treatment centers. By providing a clear biomarker, Inbiomotion enables a more precise and effective use of bisphosphonates, potentially preventing unnecessary treatment and side effects for patients who would not benefit, while improving outcomes for those who will. The company has secured significant funding through various rounds, including a notable €11.1 million Series A financing, to advance the clinical validation and market entry of its MAF test.

Keywords: precision medicine, breast cancer, diagnostic test, MAF gene, biomarker, oncology, metastasis, bisphosphonates, personalized medicine, in-vitro diagnostics